Tolvaptan (Jynarque)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Autosomal Dominant Polycystic Kidney Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Product first approved 2018FDA label
EU
  • Jinarc: slow progression of cyst development and renal insufficiency in autosomal dominant polycystic kidney disease (CKD stage 1-3 at start, rapidly progressing)
Product first approved 2015EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Autosomal Dominant Polycystic Kidney Disease
NCT02964273 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2016-09-23 – 2021-11-17 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
What this study did
NCT02251275 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-10-17 – 2018-11-09 · Polycystic Kidney, Autosomal Dominant
What this study did
NCT01214421 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-05-26 – 2016-02-29 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
What this study did
Phase 2 (5)
Autosomal Dominant Polycystic Kidney Disease
NCT03541447 · Mario Negri Institute for Pharmacological Research
2018-12-12 – 2021-12-23 · Autosomal Dominant Polycystic Kidney Disease
What this study did
NCT01451827 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2011-10 – 2013-07 · Autosomal Dominant Polycystic Kidney Disease
What this study did
NCT01336972 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-10 – 2011-11 · Autosomal Dominant Polycystic Kidney Disease
What this study did
NCT01210560 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-10 – 2011-06 · Autosomal Dominant Polycystic Kidney Disease
What this study did
NCT00413777 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-12 – 2010-06 · Polycystic Kidney, Autosomal Dominant
What this study did
Phase 4 (1)
Autosomal Dominant Polycystic Kidney Disease
NCT03596957 · Lisbet Brandi
2018-09-12 – 2020-04 · Autosomal Dominant Polycystic Kidney
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Autosomal Dominant Polycystic Kidney Disease
NCT03764605 · Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
2019-01-30 – 2022-01-30 · ADPKD
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Autosomal Dominant Polycystic Kidney Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tolvaptan (Jynarque): this drugApprovedSmall moleculeVasopressin V2 receptorPartial signal
NCT02160145: Annualized change in eGFR (REPRISE trial): -2.34 mL/min/1.73m2/year tolvaptan vs -3.61 mL/min/1.73m2/year placebo; difference 1.27 mL/min/1.73m2/year (95% CI 0.86-1.68), 35% reduction in decline, P<0.001
NCT00428948: Total kidney volume growth over 36 months: tolvaptan 2.78% per year vs placebo 5.61% per year; difference -2.71 percentage points per year (95% CI -3.27 to -2.15), p<0.0001 (n=819 and 458 analysed) (CT.gov posted results).
OPC-61815 (Samtasu)
Phase 3(overall)
Small moleculeVasopressin V2 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Tolvaptan (Samsca)
Phase 3(overall; approved for another use)
Small moleculeVasopressin V2 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
VX-407Phase 2Small moleculePolycystin-1 (PKD1 variants)not yet gradedNo reviewed efficacy summary in this indication
AZD1613Phase 1Monoclonal antibodyPAPP-Anot yet gradedNo reviewed efficacy summary in this indication
GSK4771261Phase 1Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
Farabursen
—(overall)
RNA / oligonucleotidemiR-17not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 April 2025ApprovalFirst generic tolvaptan (Jynarque strengths) approved for Lupin; US launch 2025-05-13 with 180-day exclusivity
US, FDA · Lupin · Source ↗